Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.
about
Stem cell-based therapies in inflammatory bowel disease: promises and pitfallsA systematic review of disease-related stigmatization in patients living with inflammatory bowel diseaseRecent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?Effect of the Diagnosis of Inflammatory Bowel Disease on Risk-Adjusted Mortality in Hospitalized Patients with Acute Myocardial Infarction, Congestive Heart Failure and PneumoniaAllogeneic guinea pig mesenchymal stem cells ameliorate neurological changes in experimental colitis.Exploiting the UMLS Metathesaurus for extracting and categorizing concepts representing signs and symptoms to anatomically related organ systems.Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.Underestimation of Smoking Rates in an East Asian Population with Crohn's Disease.Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.The use of prognostic factors in inflammatory bowel diseases.Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?Patient-relevant endpoints in inflammatory bowel diseases--have changes occurred in Germany over the past twelve years?Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010.Intestinal colonization with phylogenetic group B2 Escherichia coli related to inflammatory bowel disease: a systematic review and meta-analysis.Incidence Rates and Predictors of Colectomy for Ulcerative Colitis in the Era of Biologics: Results from a Provincial Database.Preventing Collateral Damage in Crohn's Disease: The Lémann Index.VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell (Treg) phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease.The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same?The biologics of ulcerative colitis.Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea.Incidence of Bowel Surgery and Associated Risk Factors in Pediatric-Onset Crohn's Disease.Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009.Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study.The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Örebro, Sweden 1963-2005.Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009.Low Risk of Unemployment, Sick Leave, and Work Disability Among Patients with Inflammatory Bowel Disease: A 7-year Follow-up Study of a Danish Inception Cohort.Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis.Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.Assessment of factors associated with smoking cessation at diagnosis or during follow-up of Crohn's disease.Psychological Considerations and Interventions in Inflammatory Bowel Disease Patient Care.Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance.Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study.
P2860
Q26745715-0FEABEC2-4158-499A-8B83-8907C979ACE1Q26750421-2E8362FC-E1E0-4A70-8FA1-C20B9BFC22B8Q30242073-2134B7B5-5B73-4C2B-805C-0467DA3767E7Q36079802-C3ABF197-E788-4BF4-9768-858B7F116D38Q36419634-C93B926B-F7DB-4A95-9C47-8DAEA60A2D4BQ36912557-6D9B845C-50AF-4971-90FB-9EFDA96DE520Q37521805-33A65760-4E4D-423E-BE52-7682AF89EDBFQ37573918-8C1B2837-7166-4725-9C3C-377CAFF7BC09Q37691599-435AC77C-A677-43DB-A856-9DB74488BCA0Q38254878-F6FA43F6-A42E-4E15-A288-4D8D80643D9DQ38285779-434BAAA7-23C4-40EB-89BC-FD9FDE0EA485Q38367790-A0E375FF-9D25-4E57-B8D2-026A7A369AB5Q38372199-8A0BA8B7-059F-4DFF-B5F9-1BA3414D556DQ38441094-103C1372-C83C-4450-BE94-AF7405BEAF9DQ38624613-22CCF181-7358-4FA5-A2A2-8BFEDF05444BQ38690180-5275EE9C-C721-4D80-80DD-366873E42EABQ38804021-DA07484C-C5A9-4FD5-8CF1-F028CB4BD6EFQ38968369-B56645AA-AA55-4B07-BBE4-2EE32779D043Q38982297-ADA9D7A2-1D28-432B-92CC-B54325397ED1Q39037681-3974EC90-49E6-48AA-B340-48D0AB58753EQ39073920-5399A006-E1E6-41C4-95EF-E49E702B5351Q39276665-2881458E-CFDC-45EF-82F0-2B505096284DQ39645051-9B8C0C7E-EBE7-4255-9AE9-94D53035C9F3Q39818677-8239D0CC-58E9-4B34-BAAB-B192A40ABAA5Q40052034-9ACBE843-F7E3-4DB2-A140-0CD94B9CB208Q40453690-2D81FAC7-9295-44FF-B433-6866911F1472Q40515016-2D5DF832-607C-4F28-BB6F-DA98D3F21926Q40579809-0C5218E6-1A76-4A7A-9CB1-4A993DA33CDFQ40747902-D032884A-B485-4D4C-AD6E-60DD37D735A5Q42242578-185AB160-0E8E-4E2D-ABDF-EA3BF0FC9E4DQ42364630-B4E8D2A6-F9C1-434D-82FB-177023B8ED41Q46345854-F29180AD-6DDA-476B-830E-548494ACB40AQ47100161-A10C18F2-B093-4E9D-9CAC-64A6F3B1534EQ47340062-C7D05841-E143-40DD-8A04-E01B13E6E2B7Q47570834-EA30F02B-8979-4791-A405-0B3309C4660DQ47769305-8BD83894-F7F9-43F6-BEE8-13D574E4D3A3Q48223667-D9CBAEA6-57C6-41B0-87BE-CC7C927FA10BQ49961881-CED4AF14-0E62-41C5-B798-9ED1F26F72C8Q50319887-E909AF15-634E-40B0-8345-9C9D963AA0ABQ50562337-B8E2AFFF-2847-44D8-80A4-BB44ADFE5B0B
P2860
Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Disease course and surgery rat ...... a of immunomodulating therapy.
@en
Disease course and surgery rat ...... a of immunomodulating therapy.
@nl
type
label
Disease course and surgery rat ...... a of immunomodulating therapy.
@en
Disease course and surgery rat ...... a of immunomodulating therapy.
@nl
prefLabel
Disease course and surgery rat ...... a of immunomodulating therapy.
@en
Disease course and surgery rat ...... a of immunomodulating therapy.
@nl
P2093
P2860
P356
P1476
Disease course and surgery rat ...... a of immunomodulating therapy.
@en
P2093
Bo G Bengtsson
Flemming Bendtsen
Marianne K Vester-Andersen
Michelle V Prosberg
Mikael Andersson
Pia Munkholm
Thomas Blixt
P2860
P304
P356
10.1038/AJG.2014.45
P407
P577
2014-03-18T00:00:00Z